EQRX abandons drug pricing business plan; doctors find a surprise aid to ease start of addiction treatment

Taking stock of the drug industry, from the lab to the medicine chest

May 8, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | EQRX abandons business plan around drug pricing, cuts jobs and programs The company will focus on only one of several medicines it is developing and on finding new drugs it can acquire. By Matthew Herper To ease start of addiction treatment, doctors find surprise aid: ketamine Fentanyl's potency has meant that patients transitioning to buprenorphine treatment can experience withdrawal symptoms. By Lev Facher Opinion: The amoxicillin shortage continues to force pediatricians and families to scramble While the tripledemic has thankfully waned, the amoxicillin shortage has not. Congress, the FDA, and drug manufacturers must act. By Nishant Pandya Sarah Gonzalez for STAT 'Robbing Peter to pay Paul': Obesity experts debate risks of new weight loss drugs At the same time, public discourse around these newest weight loss drugs is helping break down another major barrier to tackling obesity. By Ambar Castillo STAT+ | Geisinger board member: Local consolidation influenced Kaiser-Geisinger deal Geisinger board member Gail Wilensky said local consolidation in Pennsylvania influenced the Kaiser-Geisinger deal. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser